Dnaprint Genomics Stock Net Income
Fundamental analysis of DNAPrint Genomics allows traders to better anticipate movements in DNAPrint Genomics' stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Net Loss | -11.1 M | -11.7 M | |
| Net Loss | -11.1 M | -11.7 M | |
| Net Loss | -11.1 M | -11.7 M | |
| Net Loss | (0.03) | (0.03) |
DNAPrint | Net Income | Build AI portfolio with DNAPrint Stock |
DNAPrint Genomics Company Net Income Analysis
DNAPrint Genomics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current DNAPrint Genomics Net Income | (12.35 M) |
Most of DNAPrint Genomics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNAPrint Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
DNAPrint Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for DNAPrint Genomics is extremely important. It helps to project a fair market value of DNAPrint Stock properly, considering its historical fundamentals such as Net Income. Since DNAPrint Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DNAPrint Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DNAPrint Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
DNAPrint Operating Income
Operating Income |
|
Based on the recorded statements, DNAPrint Genomics reported net income of (12.35 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.
DNAPrint Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNAPrint Genomics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics of similar companies.DNAPrint Genomics is currently under evaluation in net income category among its peers.
DNAPrint Fundamentals
| Return On Asset | -1.05 | ||||
| Profit Margin | (2.36) % | ||||
| Operating Margin | (7.31) % | ||||
| Current Valuation | 5.64 M | ||||
| Shares Owned By Institutions | 0.18 % | ||||
| Price To Sales | 0.20 X | ||||
| Revenue | 2.43 M | ||||
| Gross Profit | 446.37 K | ||||
| EBITDA | (5.78 M) | ||||
| Net Income | (12.35 M) | ||||
| Cash And Equivalents | 134.35 K | ||||
| Total Debt | 240 K | ||||
| Current Ratio | 0.17 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (5.78 M) | ||||
| Number Of Employees | 24 | ||||
| Beta | 86.01 | ||||
| Market Capitalization | 386.76 K | ||||
| Total Asset | 10.27 M | ||||
| Retained Earnings | (45.53 M) | ||||
| Working Capital | (9.35 M) | ||||
| Current Asset | 1.89 M | ||||
| Current Liabilities | 11.24 M | ||||
| Net Asset | 10.27 M |
About DNAPrint Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DNAPrint Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNAPrint Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNAPrint Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether DNAPrint Genomics is a strong investment it is important to analyze DNAPrint Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DNAPrint Genomics' future performance. For an informed investment choice regarding DNAPrint Stock, refer to the following important reports:Check out DNAPrint Genomics Piotroski F Score and DNAPrint Genomics Altman Z Score analysis. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DNAPrint Genomics. If investors know DNAPrint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DNAPrint Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DNAPrint Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DNAPrint Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DNAPrint Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.